GPATCH2L

Across TCGA pan-cancer cohorts, GPATCH2L RNA is linked to patient survival in 29 of 34 cancer types, making it the most broadly survival-associated GPATCH2L data layer compared with 7 for mutation status and 1 for mass-spec protein.

The strongest signal is observed in mesothelioma (MESO), where higher GPATCH2L RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated GPATCH2L expression acts as an unfavorable survival marker, although some lineages such as KIRC and UCS show a favorable association.

MESO, ACC, and KIRC are the cancer types where GPATCH2L RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
MESO	DFS	Median	III,IV	0.287	0.516	.003	58	view →
ACC	DFS	Median	All	0.346	0.785	<.001	54	view →
KIRC	DFS	Median	All	0.772	0.489	<.001	48	view →
LUSC	DFS	Quartile	III,IV	0.206	0.951	<.001	26	view →
LIHC	OS	Median	All	0.701	0.857	.001	26	view →
UCS	DFS	Tertile	IV	0.932	0.321	.024	24	view →
BRCA	DFS	Quartile	III,IV	0.654	0.466	.014	23	view →
THYM	DFS	Median	All	0.967	0.657	.006	16	view →
CESC	DFS	Quartile	All	0.641	0.825	.008	16	view →
GBM	DFS	Tertile	All	0.464	0.195	.004	15	view →
UVM	DFS	Tertile	III,IV	0.279	0.780	.017	10	view →
SCLC	OS	Tertile	II,III,IV	0.670	0.334	.005	10	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 29 lineages.

GPATCH2L–MESO (DFS)

Open the MESO breakdown →